Reuters logo
BRIEF-Aduro Biotech announces advancement of adu-s100 into global combination trial with pdr001 for the treatment of solid tumors and lymphomas
September 26, 2017 / 12:48 PM / in a month

BRIEF-Aduro Biotech announces advancement of adu-s100 into global combination trial with pdr001 for the treatment of solid tumors and lymphomas

Sept 26 (Reuters) - Aduro Biotech Inc

* Aduro Biotech announces advancement of ADU-S100 into global combination trial with PDR001 for the treatment of solid tumors and lymphomas

* Aduro Biotech - ‍trial, which is being conducted in collaboration with Aduro’s partner, Novartis, is expected to enroll about 175 patients at sites​ Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below